...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Resverlogix’s BETonMACE Phase 3 Epigenetics Trial Completes Final Safety Visits

Would they have not known the total patient-years on or before June 12th, 2019?

Top-line results expected to be announced in September 2019, which includes primary and selected secondary endpoints.

Wondering what the selected secondary endpoints would be?

 

Koo   

 

 

Share
New Message
Please login to post a reply